Gp96-igg1-fc Fusion Protein And Hla-a1 Expressing Uses, Dosage, Side Effects and more
Gp96-igg1-fc Fusion Protein And Hla-a1 Expressing is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).
| Trade Name | Gp96-igg1-fc Fusion Protein And Hla-a1 Expressing |
| Generic | Viagenpumatucel-L |
| Viagenpumatucel-L Other Names | Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine, Viagenpumatucel l, Viagenpumatucel-L |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
